# Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study

> **NCT07550452** · NA · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** Ivarmacitinib Sulfate Tablets

## Key facts

- **NCT ID:** NCT07550452
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-07-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550452, "Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07550452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*